LRP5 and colorectal carcinoma: Nie and colleagues showed that the activation of LRP5 in turn drives cells towards a CSC phenotype and consequently supports chemoresistance of CRC cells through activation of both the Wnt/β-catenin and IL-6/STAT3 signaling pathways [65].